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Context. To describe a case of invasive ductal carcinoma of the breast in a transgender male receiving testosterone therapy for
gender-affirming treatment. Case Description. A 28-year-old transgender male receiving intramuscular testosterone was found
to have a breast mass on ultrasound after self-exam revealed a palpable breast lump. Ultrasound-guided breast biopsy revealed
estrogen receptor/progesterone receptor (ER/PR) negative, human epidermal growth factor receptor-2 (HER-2) positive, invasive
ductal carcinoma of the left breast. He underwent neoadjuvant and adjuvant chemotherapy along with bilateral mastectomy. At
patient request, his testosterone injections were permanently discontinued. Conclusion. Fewer than 20 cases of breast cancer in
transgender male patients have been reported in medical literature. While studies have shown increased risk of breast cancer in
postmenopausal women with higher testosterone levels, data regarding premenopausal women is conflicting and little is known
about breast cancer risk in transgender individuals receiving gender-affirming hormone therapy (GAHT), with inconclusive results
regarding correlation between testosterone therapy and breast cancer. More research is required to evaluate whether a possible
increased risk of breast cancer exists for transgender men receiving gender-affirming therapy.
1. Introduction
Testosterone is used in the transgender male population in
order to induce masculinization; however the association
between testosterone and breast cancer risk is not well
defined. There are a small number of cases documenting
breast cancer in transgender male patients receiving mas-
culinizing GAHTwith current studies showing a possible but
inconclusive correlation between higher doses of testosterone
and increased breast cancer risk.
2. Case Presentation
A 28-year-old transgender man who had been receiving mas-
culinizing hormone therapy presented with a self-palpated
left breast mass. Past medical history included gender incon-
gruence for which the patient had been receiving weekly
testosterone injection therapy for one year prior to presen-
tation. Gynecological history was unremarkable and menses
had stopped approximately one month into gender-affirming
therapy. Home medications included intramuscular testos-
terone enanthate 100 mg weekly, multivitamin, and vitamin
D supplement. He had never smoked and denied alcohol
or illicit drug use. Family history included mother with
hypertension, father with diabetes mellitus, paternal great
grandmother with breast cancer,maternal great grandmother
with ovarian cancer, maternal grandmother with lung cancer,
and maternal grandfather with gastric cancer.
On physical exam, the patient was a well-appearing male
with moderate growth of facial hair. Cardiac, pulmonary,
abdominal, neurologic, and musculoskeletal exam were all
unremarkable. Breast exam revealed a palpable left upper
breast lump without skin dimpling or changes in pigmenta-
tion. His lab values included total testosterone ranging over
the year from 544 to 970 ng/dL (reference range for men:
270-1,734), hemoglobin and hematocrit of 15.1 g/dL (reference
range formen: 12.5-16.3) and 44.2% (reference range formen:
36.7-47.0), and normal hepatic function panel.
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Figure 1: Breast ultrasound: lobulated solid left breast mass at 11:00,
approximately 0.8 × 1.1 × 1.4 cm.
3. Investigation
Breast ultrasound revealed a 1.4 × 0.8 × 1.1 cm oval, hypoe-
choic left upper breast mass with indistinct margins which
was suspicious for malignancy and corresponded to the
palpable lump on physical exam (Figure 1). Ultrasound-
guided breast biopsywas performedwith pathology revealing
nuclear grade 3, estrogen receptor (ER)/progesterone recep-
tor (PR) negative, human epidermal growth factor receptor
2 (HER-2) positive, invasive ductal carcinoma of left breast.
Genetic testing was negative for androgen receptor (AR)
mutation and breast cancer type 1 and 2 (BRCA-1 and
BRCA-2) mutations but did show a variant of undetermined
significance (VUS).
4. Treatment and Outcome
After diagnosis of invasive ductal carcinoma of the left breast,
a lengthy discussion was held with the patient regarding
potential risks of continuing testosterone therapy versus
risks to the patient’s well-being from cessation of gender-
affirming hormone therapy. The patient opted to discontinue
the testosterone. He underwent neo-adjuvant chemotherapy
with docetaxel, carboplatin, pertuzumab, and trastuzumab.
He then underwent bilateral nipple-sparing mastectomy with
surgical pathology showing left breast ductal carcinoma in
situ with negative margins and no lymph node involve-
ment. The patient later had a total laparoscopic hysterec-
tomy with bilateral salpingo-oophorectomy and remains on
trastuzumab therapy at this time.
5. Discussion
Transgender male patients typically achieve masculiniza-
tion through gender-affirming therapy with testosterone.
Although there is strong evidence to link higher estrogen
levelswith breast cancer development [1, 2], there ismounting
but inconclusive evidence suggesting a link between higher
circulating androgen levels and the development of breast
cancer [3–9]. The patient population in these studies has
been female and, to date, there have been fewer than 20
reported cases of breast cancer related to testosterone therapy
in transgender men [3–7, 10]. Two proposed mechanisms of
excess androgen-related breast cancer development include
aromatization of testosterone to estrogens in peripheral
tissues and the activation of androgen receptors which
leads to cellular growth and proliferation, particularly in
mammary tissues [1–4, 8, 9]. Conversely, a few studies
suggest protective effects of androgens possibly via competi-
tive blockade of estrogen receptors in mammary epithelium
[8].
Studies have noted that some breast cancers which are
negative for ER and PR expression are positive for AR
expression, suggesting increased androgen receptor positivity
as its own risk factor in the development of breast cancers [3].
In our case, expressions of ER, PR, and AR were all negative
however HER-2 expression was positive. Some case reports
of breast cancer development in transgender men receiving
testosterone therapy noted increased expression of HER-2
but the mechanism of testosterone-related overexpression
of HER-2 is unknown [3, 11]. Of the cases revealed in the
literature, the types of breast cancer were variable, consisting
of invasive ductal carcinoma, neuroendocrine carcinoma,
and tubular adenocarcinoma [3–7, 11]. The strongest cor-
relation of androgen levels and risk of breast cancer was
in hormone receptor positive tumors including ER/PR and
androgen receptor (AR) positivity [2, 3]. One study which
followed five transgender male patients two years after
initiation of testosterone therapy found upregulation of over
200 genes associated with breast cancer-unique expression
[3].
No consistent guidelines exist regarding the continuation
of GAHT following breast cancer treatment in transgender
men [3–7, 10]. Published reports suggest that most patients
are restarted on low-dose testosterone therapy with or with-
out an aromatase inhibitor to prevent peripheral conversion
of testosterone to estrogens [3, 4, 6, 7, 11]; however the
available evidence on the risk of breast cancer recurrence
with continuation of masculinizing GAHT is conflicting.
Prophylactic use of aromatase inhibitors is currently under
investigation and its effectiveness is unknown [3–7]. None of
the patients who resumed low-dose testosterone therapy had
breast cancer recurrent at 2-5 years’ follow-up in a limited
number of case reports [3–7]. Other studies of recurrence
among transgendermen receivingmasculinizingGAHThave
indicated that bilateral mastectomy does not negate future
risk of cancer development in residual breast tissue [4, 5]. In
individual high-risk cases, such as in this case with extensive
family history of cancer, pretreatment screening with breast
imaging may be warranted prior to initiating GAHT. In our
particular case, the patient elected to permanently discon-
tinue testosterone therapy.Whether such cessation of therapy
was necessary is uncertain and more research is required
to assess benefits of therapy versus risk of breast cancer
recurrence.
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Data Availability
The review of collective case report data used to support the
discussion findings in this case report are included within the
article within the following references [1–11].
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